icon-folder.gif   Conference Reports for NATAP  
 
  62th Annual Meeting of the American Association for the Study of Liver Diseases San Francisco 2011 Nov 6-9 Back grey_arrow_rt.gif
 
 
 
Projections Using Decision-Analytic Modeling of Long-Term Clinical Value of Telaprevir for the Treatment of HCV Patients Who Had Failed Prior Peginterferon/Ribavirin Treatment
 
 
  Reported by Jules Levin
AASLD Nov 5-8 2011 SF
 
Baris Deniz, MSc1; Anita J Brogan, PhD2; Jeffrey D Miller, MS3; Sandra E Talbird, MSPH2; James R Thompson, MS2
1Vertex Pharmaceuticals Incorporated, Cambridge, MA, United States; 2RTI Health Solutions, Research Triangle Park, NC, United States; 3RTI Health Solutions, Waltham, MA, United States

AASLD1.gif

AASLD2.gif

AASLD3.gif

AASLD4.gif

AASLD5.gif

AASLD6.gif

AASLD7.gif

AASLD8.gif

AASLD9.gif

AASLD10.gif